In conclusion, an immune signature constructed using HLA-DQA2, HOXA3, and SAA2 exhibited significant and specific prognostic value for IDH1mt glioma, while the high-risk group classified by the signature had a high benefit from ICB. This evidence concerns the gene HOXA3 and glioma.